AI ECG Algorithm for Detecting LV Systolic Dysfunction
Prospective Observational Cohort Study of Deep Learning-based ECG Algorithm for Detecting Left Ventricular Systolic Dysfunction
研究概览
详细说明
Left ventricular systolic dysfunction (LVSD) is associated with an increased risk of heart failure, hospitalization, and mortality. Although transthoracic echocardiography is the standard method for assessing left ventricular ejection fraction (LVEF), its widespread use as a screening tool is limited by availability, cost, and the need for specialized personnel. Artificial intelligence (AI)-based electrocardiography (ECG) algorithms have emerged as promising tools for identifying patients with reduced LVEF using routinely acquired ECG signals.
DeepECG LVSD is a deep learning-based ECG algorithm developed to detect LVSD (LVEF ≤40%) from standard 12-lead ECG recordings. Previous retrospective validation studies demonstrated high diagnostic performance; however, prospective clinical validation in real-world practice remains limited.
The purpose of this prospective observational cohort study is to evaluate the diagnostic performance and clinical utility of DeepECG LVSD in adult patients undergoing both ECG and transthoracic echocardiography at Ajou University Hospital. Approximately 15,000 patients aged 19 years or older who have undergone ECG and echocardiography within 30 days will be enrolled.
The primary objective is to assess the accuracy of the AI algorithm for detecting LVSD using echocardiographic LVEF as the reference standard. Diagnostic performance will be evaluated using the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy.
Secondary objectives include evaluating the association between AI-predicted LVSD and short-term clinical outcomes, including 30-day all-cause mortality, emergency department visits, and heart failure rehospitalization. Exploratory subgroup analyses will assess algorithm performance according to demographic and clinical characteristics, including age, sex, heart failure status, chronic kidney disease, hypertension, diabetes mellitus, and the interval between ECG and echocardiography.
This study is designed as a minimal-risk observational study and will provide prospective evidence regarding the effectiveness of AI-enabled ECG screening for LVSD in routine clinical practice. Findings from this study may support broader implementation of AI-based ECG tools for the early identification of patients at risk for heart failure and reduced left ventricular systolic function.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:MOONSEUNG SOH, MD
- 电话号码:+82-31-219-5111
- 邮箱:mssoh7701@gmail.com
学习地点
-
-
Gyeonggi-do
-
Suwon、Gyeonggi-do、韩国、16499
- 招聘中
- Ajou University School of Medicine
-
接触:
- MOONSEUNG SOH, MD
- 电话号码:+82-31-219-5111
- 邮箱:mssoh7701@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Adults aged ≥19 years.
- Patients who underwent both transthoracic echocardiography and 12-lead electrocardiography (ECG) at Ajou University Hospital in the outpatient, inpatient, or emergency department setting.
- ECG and echocardiography performed within 30 days of each other.
Exclusion Criteria:
- Interval between ECG and echocardiography greater than 30 days.
- Missing or corrupted original ECG waveform data (XML or HL7 format).
- Presence of an implanted cardiac device, including a permanent pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT) device.
- Missing age, sex, or left ventricular ejection fraction (LVEF) data.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Adults aged ≥19 years with ECG and echocardiography performed within 30 days
Adult patients aged 19 years or older who underwent both transthoracic echocardiography and electrocardiography (ECG) within 30 days of each other
|
There is no intervention group
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
AUROC for detection of LVSD (LVEF ≤40%)
大体时间:During procedure
|
Diagnostic performance including AUROC, sensitivity, specificity, positive predictive value, negative predictive value, and accuracy.
|
During procedure
|
合作者和调查者
出版物和有用的链接
一般刊物
- Lopez-Jimenez F, Alger HM, Attia ZI, Barry B, Chatterjee R, Dolor R, Friedman PA, Greene SJ, Greenwood J, Gundurao V, Hackett S, Jain P, Kinaszczuk A, Mehta K, O'Grady J, Pandey A, Pullins C, Puranik AR, Ranganathan MK, Rushlow D, Stampehl M, Subramanian V, Vassor K, Zhu X, Awasthi S. A multicenter pragmatic implementation study of AI-ECG-based clinical decision support software to identify low LVEF: Clinical trial design and methods. Am Heart J Plus. 2025 Mar 21;54:100528. doi: 10.1016/j.ahjo.2025.100528. eCollection 2025 Jun.
- Choi J, Lee S, Chang M, Lee Y, Oh GC, Lee HY. Author Correction: Deep learning of ECG waveforms for diagnosis of heart failure with a reduced left ventricular ejection fraction. Sci Rep. 2022 Oct 13;12(1):17191. doi: 10.1038/s41598-022-22012-7. No abstract available.
- Attia ZI, Kapa S, Lopez-Jimenez F, McKie PM, Ladewig DJ, Satam G, Pellikka PA, Enriquez-Sarano M, Noseworthy PA, Munger TM, Asirvatham SJ, Scott CG, Carter RE, Friedman PA. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Nat Med. 2019 Jan;25(1):70-74. doi: 10.1038/s41591-018-0240-2. Epub 2019 Jan 7.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.